Thermo Fisher Scientific has announced a new collaboration with RoosterBio to enhance the availability of cell and exosome therapies for treating degenerative diseases, a development that aligns with their focus on advanced therapy manufacturing. Despite this promising partnership, the company's stock was flat over the past week, amidst a broader market rally led by strong tech earnings from companies like Microsoft and Meta. With the S&P 500 and Dow rising for consecutive sessions, Thermo Fisher's latest advances may have added some weight to these positive market trends rather than diverging from them significantly.

We've discovered 2 possible red flags for Thermo Fisher Scientific that you should be aware of before investing here.

Find companies with promising cash flow potential yet trading below their fair value.

Despite the initial stagnation in Thermo Fisher Scientific's stock following the announcement of its collaboration with RoosterBio, the potential impact on the company’s future growth and innovation narrative is significant. This collaboration could enhance their capability in advanced therapy manufacturing, potentially bolstering revenue and earnings forecasts. If realized effectively, these developments might help the company align better with the expected revenue growth of 5.3% annually, as well as support the 17.6% projected increase in profit margins over the next three years. As the market digests this news, it may contribute to narrowing the share price discount to analysts' consensus price target of US$570.17.

Reflecting on Thermo Fisher’s performance over a five-year period, the company’s total shareholder return was 29.56%. This overall gain offers a broader perspective, especially given that over the past year, the stock's performance matched the US Life Sciences industry, which experienced a 25.8% decline. While the current share price of US$427.53 remains below the analyst target of US$575, the strategic partnerships and innovation-focused developments potentially lay the groundwork for future upward price movements, as projected by analysts. Investors may want to consider that despite recent underperformance against market indices in the short term, the longer-term trajectory and strategic initiatives continue to be key elements shaping the company’s potential upside.

In light of our recent valuation report, it seems possible that Thermo Fisher Scientific is trading behind its estimated value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NYSE:TMO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com